Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Investor Presentation (August 2020)
21 slides from Optiscan Imaging's investor presentation, Aug 25, 2020
Slide 1: Optiscan Investor Presentation
ASX Announcement 25 August 2020 Optiscan Investor Presentation Optiscan Imaging Ltd (“Optiscan”) is participating in a Finance New Network virtual Investor Event today. Attached is the presentation to be delivered by Optiscan’s Executive Chair, Darren Lurie. - ends - This announcement has been autho
Slide 2: Optiscan Imaging Ltd (ASX:OIL)
Optiscan Imaging Ltd (ASX:OIL) Enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection
Slide 3: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 25 August 2020. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may
Slide 4: Notice
Notice Not an offer or financial productadvice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure docu
Slide 5: Corporate Snapshot
Corporate Snapshot Board Total Securities on Issue Darren Lurie – Executive Chair ▪ 477,778,800 Ordinary Shares B.LLB (Hons) and B.COM (Hons) ▪ 25,600,000 unlisted options Former Group CFO and Head of Corporate Development for EduCo International (an investee company of Baring Private Equity Asia).
Slide 6: Optiscan Introduction - Technology
OPTISCAN Introduction - Technology ❑ Hand-held Confocal Endomicroscope for Medical and Research Imaging ❑ World-leading and Patent Protected ❑ Real-time “Virtual Biopsy“ ❑ Reduced and More Targeted Biopsies ❑ Capture all Cancer Cells and reduce Tumour Margin in Surgery
Slide 7: Optiscan FIVE2 Laboratory and InVivage Clinical Systems
Optiscan FIVE2 Laboratory and InVivage® Clinical Systems 4.7 mm Diameter Tip FIVE2 (ViewnVivo) Laboratory System InVivage® Clinical System
Slide 8: Optiscan Applications and Devices
Optiscan Applications and Devices Clinical Applications and Devices: ❑ Oral Cancer - InVivage® ❑ Breast Cancer - InVivage® ❑ Neurosurgery – CONVIVO® (Carl Zeiss Meditec Co-operation) Pre-clinical Device: FIVE2 (ViewVivo®) ❑ Laboratory & Translational Experiments ❑ Medical Research Facilities and Uni
Slide 9: World Lip & Oral Cavity Cancer Incidence and Mortality
World Lip & Oral Cavity Cancer Incidence and Mortality 354,864 Total number of new cases in 20182% Of all cancer incidences 177,384 Total deaths in 2018 1.9% Of all deaths from cancer https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21492
Slide 10: Oral Cancer Market Size - United States
Oral Cancer Market Size - United States 71 National Cancer Institute (NCI) Designated Cancer Centers 900 Specialist Cancer Centers 6,146 Total US Hospitals 9,000 Oral and Maxillofacial Surgeons https://www.aaoms.org/about https://www.cancer.gov/research/infrastructure/cancer-centers/find
Slide 11: Oral Market Size - China
Oral Market Size - China ❑China: 48 Public Tertiary Dental Hospitals ❑Guangdong Province: 158 Stomatology Departments in General Hospitals, 14 Public and Private Dental Hospitals Leading Specialist Dental Hospitals: Name Location No. of Chairs Patient Volume (Out patient annually) KPMG. (2016). Comm
Slide 12: Oral Cancer Diagnosis, Survival Rates and Economic Cost
Oral Cancer Diagnosis, Survival Rates and Economic Cost Early Diagnosis Late Diagnosis Early Vs Late >80% 57% 2.5x Survival Survival Cost 80-90% Five Year 57% Five Year 2.5x More Survival Rate in Survival Rate in Economic Early Diagnosis1 Late Diagnosis1 Burden when Diagnosed Late2 1. Oral Cancer Fo
Slide 13: New InVivage User Interface Designed for Doctors
New InVivage® User Interface Designed for Doctors Squamous epithelial cells and taste bud papillae in tongue (0.5mm x 0.5mm view)
Slide 14: Optiscan - Oral Cancer Progress
OPTISCAN – Oral Cancer Progress 3 Oral Cancer Studies and Trials ❑ Received Federal Government ~1m A$ grant for 150 patient Oral Cancer Study at Melbourne Dental School (includes $260k payable to Optiscan) ❑ Trial on-going at the Memorial Sloan Kettering Cancer Centre in New York ❑ Trial on-going at
Slide 15: Breast Cancer - Most Common Cancer in Women
Breast Cancer - Most Common Cancer in Women 2.1 15% 8.5% Million 2.1 million new cases of 15% of all 8.5% of all new cancer breast cancer predicted in new Cancer cases in cases in China are breast 2018 (globally) 1 United States are breast 3 cancer 2 cancer 20-30% of lumpectomy patients currently re
Slide 16: Optiscan - Breast Cancer Surgery
Optiscan - Breast Cancer Surgery Intraoperative Assessment of Breast Cancer Surgical Margin Normal Breast Tissue • Goal: Assist breast surgeons and pathologists to provide real-time cellular assessment of surgical margin. • Benefits: Reduce risk of residual tumour, need for repeat surgery, patient e
Slide 17: CONVIVO - Carl Zeiss Meditec Co-operation
CONVIVO® – Carl Zeiss Meditech (CZM) Co-operation ❑FDA 510(k) clearance and CE Mark obtained ❑“this probably is the most exciting technology that I have seen in my career come through the laboratory.” - Mark C Preul, Neurosurgeon, Barrow Neurosurgical Institute, Arizona, United States. 297K Brain an
Slide 18: FIVE2 (Viewnvivo) Distribution Model in China
FIVE2 (Viewnvivo) Distribution Model in China ❑ Multi-distributor model in China with appointment of exclusive distributors in South, West and East China. ▪ South and West China: Guangzhou Yunxing (Purple and Blue) ▪ East China: Biotimes Technology Limited (Green) ❑ Sale of FIVE2 (ViewnVivo) Systems
Slide 19: FIVE2 (Viewnvivo) Distribution Model for Asia Pacific
FIVE2 (Viewnvivo) Distribution Model for Asia Pacific Engagement of Dr Joseph Jiafu as a consultant to assist the Company to establish distribution arrangements in Japan, Korea, Singapore and other APAC countries (excluding China). Dr Joseph Jiafu is a microscopy expert and the former Asia Pacific I
Slide 20: Outlook
Outlook ▪ Commencement of 150 patient Oral Cancer Study at the Melbourne Dental School. ▪ Commencement of Stage 3 of Breast Cancer Study at leading Melbourne hospital/s ▪ Increased geographical footprint to deliver additional FIVE2 (ViewnVivo) sales ▪ Receipt of FDA feedback on InVivage clinical reg
Slide 21: Darren Lurie, Executive Chair, Optiscan Imaging Limited
Darren Lurie Executive Chair Optiscan Imaging Limited (ASX:OIL) dlurie@optiscan.com www.optiscan.com
Optiscan Imaging — Investor Presentation (August 2020) on 6ix